Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
User uses Indian hair serum with procapil and procyanidin b2, stopped minoxidil due to allergies. Seeks advice on hair wash techniques and products for shoulder-length hair and scalp care while using hair growth serums.
PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user experienced positive hair growth results using microneedling with rosemary and mint oil, without Minoxidil, Finasteride, or RU58841. They switched from a dermaroller to a microneedling pen and targeted different scalp areas weekly.
A user is considering using verteporfin with microneedling, oral/topical minoxidil, and RU58841 to treat hair loss. They seek advice on dosage and application methods.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
KX-826, Breezula, PP405, and Stemson are potential future treatments for hair loss, with varying timelines and mechanisms like blocking DHT and stem cell activation. Users express skepticism about the timeline and mention current options like hair transplants and minoxidil.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.
A physician experienced hair thickening and new growth using microneedling and minoxidil, but stopped using topical finasteride due to side effects like reduced libido and erectile dysfunction. The physician plans to continue with microneedling and minoxidil, considering finasteride nonessential for cosmetic purposes.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
Hair loss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safety profiles, and alternative options for androgenetic alopecia.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
Microneedling with minoxidil and finasteride greatly improves hair regrowth. Using 0.5mm depth every other day boosts minoxidil absorption without side effects.
The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.
The conversation discusses the use of autologous exosomes for hair loss, questioning their effectiveness and seeking real user experiences. The user is skeptical about the treatment's legitimacy and is looking for honest feedback on its results.
Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.
The user is using minoxidil and topical finasteride for hair loss and is seeking advice on whether to use a derma pen or derma stamp for microneedling, including the appropriate length and frequency. They previously stopped oral finasteride due to side effects.
Aminexil, nanoxidil, stemoxydine, and kopexil are discussed as alternatives to minoxidil for hair growth, with concerns about dependence. Minoxidil is noted for its effectiveness in transitioning hair growth phases, but dependence is mainly linked to androgenic alopecia.
The conversation is about finding non-alcoholic minoxidil options in India due to irritation from propylene glycol-based formulations. Suggestions include Tugain 5% foam, Morr Max 5%, minoxidil gel, and Morr F Aqua plus, with OP avoiding finasteride due to side effects.